SCHEMBL15079231

SCHEMBL15079231

CC(C)n1ccc2c(C(C)(C)C)cccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.36
EZH2 Q15910 1/20 0.35
MGLL Q99685 1/20 0.33
PGR P06401 4/20 0.33
AR P10275 4/20 0.33
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
KIF11 P52732 1/20 0.32
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CCR4 P51679 1/20 0.31
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
MEN1 O00255 1/20 0.30
MITF O75030 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18593488 0.76 MEN1 (0.44) CA2ALDH1A1TSHRTDP1MGAM
SCHEMBL24481597 0.76 EZH2 (0.37) EZH2MGLLHTR2AHTR2CMGAM
SCHEMBL13090965 0.76 HTR2C (0.53) EZH2MGLLHTR2AHTR2CALDH1A1
SCHEMBL2627063 0.76 CCR4 (0.48) CA2GABRA1GABRB2KIF11ALDH1A1
SCHEMBL850473 0.74 SLC6A2 (0.44) EZH2MGLLHTR2AHTR2CMGAM
SCHEMBL12913569 0.74 HTR2C (0.39) CA2EZH2MGLLGABRA1GABRB2
SCHEMBL31188171 0.74 HTR2C (0.46) EZH2MGLLGABRA1GABRB2HTR2A
SCHEMBL4330148 0.74 HTR2C (0.46) EZH2MGLLGABRA1GABRB2HTR2A
SCHEMBL18305541 0.74 HTR2A (0.54) EZH2MGLLHTR2AHTR2CMGAM
SCHEMBL4569749 0.74 CA2 (0.39) CA2PGRARGABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 CA2 4378/4885EZH2 543/4885MGLL 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.